Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 16/20 | 0.86 |
| ▸ | BRD4 | O60885 | 5/20 | 0.69 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.69 |
| ▸ | TAF1 | P21675 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.51 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675937 | 0.93 | PLK1 (1.00) | PLK1BRD4BRDTTAF1ALK | |
| SCHEMBL1675657 | 0.91 | PLK1 (1.00) | PLK1BRD4BRDTALK | |
| SCHEMBL1560558 | 0.89 | PLK1 (0.87) | PLK1BRD4BRDTALKPLK3 | |
| SCHEMBL1560595 | 0.89 | PLK1 (1.00) | PLK1BRD4BRDTTAF1ALK | |
| SCHEMBL1560530 | 0.88 | PLK1 (0.98) | PLK1BRD4BRDTTAF1ALK | |
| SCHEMBL1675748 | 0.88 | PLK1 (0.69) | PLK1BRD4BRDT | |
| SCHEMBL12386468 | 0.88 | PLK1 (0.85) | PLK1BRD4BRDTALK | |
| SCHEMBL1675986 | 0.87 | PLK1 (0.83) | PLK1BRD4BRDTTAF1ALK | |
| SCHEMBL1559435 | 0.87 | PLK1 (0.97) | PLK1BRD4BRDTTAF1ALK | |
| Tak-960 SCHEMBL1560793 | 0.86 | PLK1 (1.00) | PLK1BRD4BRDTPLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205241-B1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-05-21 | — | — | EP | claimed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | claimed |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | US | claimed |
| EP-2205241-A1 | POLO-LIKE KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | claimed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | claimed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | claimed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2205241-A1 | POLO-LIKE KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | PLK1 1/4885BRD4 1323/4885BRDT 579/4885 |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | PLK1 1/4885BRD4 1323/4885BRDT 579/4885 |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | PLK1 1/4885BRD4 1323/4885BRDT 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.